If you've watched two people start Ozempic and get completely different results — one losing 20 pounds while the other barely notices a change — you're not imagining things. The difference is often written in their DNA.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have transformed the treatment of type 2 diabetes and obesity. But the clinical trials tell a story that gets buried in the headlines: response varies enormously between individuals, and genetics is a primary reason why.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone your gut releases after eating. They work by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling.
In the SUSTAIN and STEP trials, average weight loss on semaglutide ranged from 9–15% of body weight. But "average" masks a huge spread. Some participants lost 25%+. Others lost less than 5%. That spread is partly behavioral, partly metabolic — and increasingly, researchers are finding that genetics accounts for a meaningful portion of the variance.
The Three Key Genes
1. GLP1R (rs6923761) — The Receptor Itself
The GLP1R gene encodes the GLP-1 receptor — the exact protein that Ozempic binds to. A common missense variant, Gly168Ser (rs6923761), changes how the receptor functions. Carriers of the A allele show measurably different glycemic responses to GLP-1 receptor agonist therapy, with differential HbA1c reduction and weight loss outcomes across multiple cohorts.
If you carry the less common allele, your GLP-1 receptor may not bind semaglutide as efficiently. This doesn't mean the drug won't work — but it's one reason your response could differ from someone else's starting the same dose.
2. GIPR (rs10423928) — The GIP Receptor
Tirzepatide (Mounjaro) works on two receptors — GLP-1 and GIP. The GIPR gene variant rs10423928 has been studied extensively in the context of metabolic drug response. The landmark Dawed et al. Lancet Diabetes & Endocrinology 2023 study (n=4,571) found that carriers of the T allele responded differently to GLP-1-based therapies — with effects dependent on both drug class and baseline metabolic profile.
This is particularly relevant as tirzepatide becomes more widely used. Understanding your GIPR variant helps predict whether the dual-agonist approach is likely to provide additional benefit over GLP-1 monotherapy.
3. TCF7L2 (rs7903146) — The Metabolism Wildcard
TCF7L2 is the most replicated type 2 diabetes risk gene in GWAS history. The risk allele at rs7903146 impairs beta-cell function and reduces GLP-1-stimulated insulin secretion — meaning people with this variant may have a blunted insulin response to GLP-1 stimulation. Patients with TCF7L2 risk alleles may need higher doses or combination approaches to achieve the same glycemic control.
| Gene | Variant | Relevance |
|---|---|---|
| ABCB1 | rs1045642 | Drug transporter; affects semaglutide distribution |
| FTO | rs9939609 | Obesity risk gene; interacts with GLP-1 appetite effects |
| MC4R | rs17782313 | Appetite regulation; affects weight loss component |
| PPARG | rs1801282 | Insulin sensitivity; modifies metabolic outcomes |
What the Research Actually Shows
The landmark paper in this space is Dawed et al. (2023) in Lancet Diabetes & Endocrinology, which conducted a pharmacogenomic analysis across four RCTs with 4,571 participants treated with GLP-1 receptor agonists. Key findings:
- Genetic variants explained a statistically significant portion of variance in HbA1c reduction
- GLP1R and GIPR variants showed interaction effects with specific drug types
- TCF7L2 risk allele carriers showed attenuated response on insulin-related endpoints
- The authors concluded pharmacogenomic profiling could help guide GLP-1 RA prescribing
What This Means For You
If you're on Ozempic, Wegovy, or Mounjaro — or considering starting — your genetics can help answer questions your prescriber currently has to guess at:
- Will I be a strong, moderate, or weak responder?
- Am I better suited to a GLP-1 monotherapy or dual GLP-1/GIP agonist?
- What dose trajectory makes sense given my receptor biology?
- What other metabolic variants might affect my overall trajectory?
GLP-1 & Metabolic Response Report
Analyzes your variants at GLP1R, GIPR, and TCF7L2 — the three genes with the strongest current evidence — and contextualizes your profile against the Dawed et al. RCT data. Available as an instant unlock from your existing sequencing data.
View Report Details →Research Use Only. AuraGen reports are not FDA-cleared and do not constitute medical advice. Always discuss pharmacogenomic results with your prescribing physician before making any medication decisions.
The Bottom Line
GLP-1 receptor agonists are among the most effective metabolic drugs ever developed. But "effective" is not the same as "equally effective for everyone." The variance in response is real, measurable, and increasingly predictable.
Your DNA doesn't determine your outcome — but it does give you and your provider a significant head start.